CLS demonstrates the TRANBERG®-system at Southwest Prostate Cancer Symposium, USA
Clinical Laserthermia Systems AB (publ) participates at the conference ”23rd Annual Southwest Prostate Cancer Symposium” by exhibiting and demonstrating the TRANBERG®|Thermal Therapy System, including CLS’ mobile laser unit and single use instruments for treatment with image guided laser ablation. The conference is held at Fairmont Scottsdale Princess, Arizona, USA, April 12-15, 2018.
The 23rd Annual Southwest Prostate Cancer Symposium brings together world-renowned urologists and oncologists – experts in the management of prostate cancer – with the objective to discuss new findings and technical innovations on all aspects of diagnosis and treatment of localized and advanced disease.
- This kind of niche meetings are excellent opportunities for us to demonstrate the TRANBERG system and to make new contacts with leading physicians, who are very dedicated in finding new or additional treatment methods for prostate cancer, said Dan Mogren, CCO at CLS.
More about 23rd Annual Southwest Prostate Cancer Symposium
This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.
Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)702 – 90 33 00 E-mail: lee@clinicallaser.se
Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG®|Thermal Therapy System and specially designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immunostimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and have subsidiaries in Berlin, Germany and Boston, MA,USA, is listed Nasdaq First North under the ticker CLS B. Certified Adviser is Västra Hamnen Corporate Finance. Further information is available on the company’s website: www.clinicallaser.se